title: Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
abstract: About 2% of the world's population is estimated to be chronically infected with hepatitis C virus (HCV). These chronic carriers are at risk of developing liver cirrhosis and its complications. Successful treatment of HCV infection is associated with improved quality of life and increased survival. Antiviral approaches were formerly based on interferon and therefore all patients with a contraindication to interferon were excluded from treatment (e.g., patients with decompensated disease, severe impairment of other organs). Very recently, interferon-free combinations have become available for genotypes 2 and 3. This review focuses on the most recently reported data on the various interferon-free combinations used (namely, sofosbuvir-based combinations, the ABT-450/ombitasvir/dasabuvir/ribavirin combination, the daclatasvir/asunaprevir combination, and the MK-5172/MK-8742 combination). All these combinations yielded amazing results in terms of efficacy (90-100%), tolerability and safety. If the problem of the high cost is overcome, interferon-free therapies will lead to what has long been a chimera, namely, an HCV-free world.
authors.affiliation: Department of Clinical Medicine and Surgery, University of Naples "Federico II", via S. Pansini 5, I-80131 Naples, Italy.
authors.forename: Ivan
authors.initials: I
authors.lastname: Gentile
authors.forename: Antonio Riccardo
authors.initials: AR
authors.lastname: Buonomo
authors.forename: Emanuela
authors.initials: E
authors.lastname: Zappulo
authors.forename: Guglielmo
authors.initials: G
authors.lastname: Borgia
mesh_terms: D015081:2-Naphthylamine; D000577:Amides; D000813:Anilides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001572:Benzofurans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002219:Carbamates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003521:Cyclopropanes; D060740:Disease Eradication; D004338:Drug Combinations; D016174:Hepacivirus; D006526:Hepatitis C / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007546:Isoquinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D047029:Lactams, Macrocyclic; D047028:Macrocyclic Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011392:Proline / Q000031:analogs & derivatives; D011759:Pyrrolidines; D011810:Quinoxalines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000069474:Sofosbuvir; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014498:Uracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D014542:Uridine Monophosphate / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D014633:Valine / Q000031:analogs & derivatives
chemical_list: D000577:Amides; D000813:Anilides; D000998:Antiviral Agents; D001572:Benzofurans; D002219:Carbamates; D003521:Cyclopropanes; D004338:Drug Combinations; D007093:Imidazoles; D007546:Isoquinolines; D047029:Lactams, Macrocyclic; D047028:Macrocyclic Compounds; D011759:Pyrrolidines; D011810:Quinoxalines; D013449:Sulfonamides; C586094:ombitasvir; D012254:Ribavirin; C578009:grazoprevir; D014498:Uracil; C000589335:elbasvir; D011392:Proline; D015081:2-Naphthylamine; C588260:dasabuvir; D014542:Uridine Monophosphate; D014633:Valine; C549273:daclatasvir; C585405:paritaprevir; C571889:asunaprevir; D000069474:Sofosbuvir
keywords: ABT-450; MK-5172; MK-8742; asunaprevir; daclatasvir; dasabuvir; interferon-free; ledipasvir; ombitasvir; sofosbuvir